Amundi Exelixis, Inc. Transaction History

Amundi

$275 Billion
Q4 2024

A detailed history of Amundi transactions in Exelixis, Inc. stock. As of the latest transaction made, Amundi holds 23,805 shares of EXEL stock, worth $877,214. This represents 0.0% of its overall portfolio holdings.

Number of Shares

23,805

Previous 37,975 37.31%

Holding current value

$877,214

Previous $985,000 19.59%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 07, 2025	SELL	$25.39 - $36.46 $359,776 - $516,638	-14,170 Reduced 37.31%	23,805 $792,000
Q3 2024 Nov 13, 2024	BUY	$21.96 - $27.6 $284,206 - $357,199	12,942 Added 51.7%	37,975 $985,000
Q2 2024 Aug 14, 2024	SELL	$20.34 - $23.73 $127,755 - $149,048	-6,281 Reduced 20.06%	25,033 $562,000
Q1 2024 May 15, 2024	SELL	$20.17 - $23.93 $3.07 Million - $3.64 Million	-152,248 Reduced 82.94%	31,314 $743,000
Q4 2023 Feb 14, 2024	BUY	$19.25 - $24.13 $868,175 - $1.09 Million	45,100 Added 32.57%	183,562 $4.4 Million
Q3 2023 Nov 14, 2023	BUY	$19.04 - $22.74 $807,505 - $964,426	42,411 Added 44.15%	138,462 $3.03 Million
Q2 2023 Aug 14, 2023	BUY	$18.17 - $20.48 $1.54 Million - $1.74 Million	84,974 Added 767.12%	96,051 $1.84 Million
Q1 2023 May 15, 2023	SELL	$16.3 - $19.41 $1.84 Million - $2.19 Million	-112,923 Reduced 91.07%	11,077 $215,000
Q4 2022 Feb 14, 2023	BUY	$14.96 - $17.39 $1.86 Million - $2.16 Million	124,000 New	124,000 $1.99 Million
Q1 2022 May 16, 2022	SELL	$17.03 - $22.67 $334,043 - $444,672	-19,615 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$16.3 - $21.14 $319,724 - $414,661	19,615 New	19,615 $415,000

Others Institutions Holding EXEL

# of Institutions

564

Shares Held

251M

Call Options Held

1.45M

Put Options Held

1.13M

View Full List

About EXELIXIS, INC.

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $11.9B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

More about EXEL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Amundi, based on Form 13F filings with the SEC.

News

Stay updated on Amundi with notifications on news.

Account